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Abstract 
Objective To assess the efficacy and safety of topical calcineurin inhibitors for 
unresponsive erosive oral lichen planus (OLP). 
Design An 8-week randomized, double-blind controlled trial, followed by a six-month 
follow-up period. 
Setting Outpatients of the Oral Medicine Section, Lingotto Dental School, University of 
Turin, Italy. 
Patients Thirty patients were treated with either pimecrolimus 1% cream or tacrolimus 
0.1% ointment, both mixed with an equivalent amount of 4% hydroxyethyl cellulose gel. 
Intervention The medications were to be applied twice daily for 2 months as follow: finger 
rub application on dried lesions after meals without eating, drinking or speaking for at 
least half an hour afterwards. Each patient was examined at the beginning of therapy, and 
then every two weeks during the treatment and every 3 months of follow-up. 
Main Outcome Measures (i) To compare the effectiveness of topically applied 
pimecrolimus and tacrolimus; (ii) to evaluate which is more cost-effective; (iii) to determine 
which drug is faster in reducing signs and symptoms and (iv) which gives the longest 
remission.  
Results Both drugs were effective at inducing clinical improvement, with no statistical 
difference. Pimecrolimus creams revealed a significantly better stability of the therapeutic 
effectiveness (P=.031). 
Conclusion Both medications would currently appear to be a treatment of choice for 
patients with unresponsive atrophic-erosive OLP. Pimecrolimus seemed to be more 
effective in providing long-term resolution of sings and symptoms. Future efforts are 
however needed to obtain more objective evidence of the benefit of these medications in 
the treatment of immunologically mediated oral mucosal lesion. 
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Introduction and background 
Oral lichen planus (OLP) is a chronic inflammatory disease, affecting nearly 1-2 % of the 
population; its lesions are habitually chronic, potentially premalignant, hardly ever undergo 
spontaneous remission, and are frequently a source of morbidity.1 To date, the precise 
aetiology remains unknown but it possibly represents a cell-mediated immunological 
response to an induced antigenic change in the skin or mucosa in predisposed patients.2-4 
Proposed therapies are usually symptomatic and numerous drugs have been used, but 
recently, it has been published that there is insufficient evidence to support the 
effectiveness of any specific treatment as being superior.5 To date OLP management is 
commonly empirical, with no adequate control groups or corrected study designs;6-9 
moreover, although topical steroids are considered first line treatment for symptomatic 
OLP, no randomized controlled clinical trials have ever compare steroids with placebo.5 
Clobetasol propionate appeared to be one of the most effective topical steroid, as in an 
adhesive base led to complete remission in 56-75% of patients with symptomatic 
OLP.1,5,10,11 Unfortunately, some patients are refractory to topical corticosteroids. For this 
reason, recently, topically applied calcineurin inhibitors have been introduced for the 
treatment of OLP, founded to reduce signs and symptoms associated to OLP with little 
incidence of adverse effects.5,12 Pimecrolimus and tacrolimus are topical calcineurin 
inhibitors that bind to macrophillin-12 and afterwards inhibit dephosphorylation of nuclear 
factor of activated T cells by calcineurin, reducing the production of TH1 cytokines.13 
To the best of our knowledge, direct evaluation of the efficacy of topically applied 
pimecrolimus and tacrolimus in the treatment of atrophic-erosive OLP, refractory to topical 
steroids, is still lacking. Therefore, the aim of our study was: (i) to compare the 
effectiveness of topically applied pimecrolimus and tacrolimus for the palliative care of 
symptomatic OLP in a double-blind and randomized protocol, (ii) evaluating which is more 
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cost-effective; (iii) to determine which drug is faster in reducing signs and symptoms during 
the first two weeks of treatment and (iv) to determine which gives the longest remission 
from signs and symptoms.  
 
Methods 
Study design 
An 8-week randomized, double-blind controlled trial was designed to measure the efficacy 
and safety of two different topical calcineurin inhibitors in the treatment of OLP. Local 
ethical committee approval was obtained before the trial started and all patients gave 
written informed consent. The study was divided into two phases: phase I consisted of 
topical treatment for 2 months; phase II was a six-month follow-up period without therapy. 
Patients were randomly divided into two groups. Randomization was performed using 
computer-generated random number tables. The first group of patients received 
pimecrolimus 1% cream mixed with a hydroxyethyl cellulose adhesive gel, whereas the 
second group of patients received tacrolimus 0.1% ointment in the same adhesive 
medium. The medication was distributed in identical containers, packed by someone who 
was unaware of the study. The coded tubes were consecutively numbered according to 
the randomization list which was prepared and retained by a single clinician (R.B.). During 
treatment, neither the physicians nor the patients knew which of the two medications they 
were using. 
Patients 
Consecutive Caucasian patients, attending the Oral Medicine Section of the Department of 
Biological Sciences and Human Oncology, University of Turin, between June 2010 and 
January 2012, were enrolled. 
The inclusion criteria were: 
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-Histological diagnosis of OLP on the basis of WHO criteria:14 hyperkeratosis of the 
superficial epithelial layers, vacuolar degeneration of the germinative layer of the 
epithelium and band-like sub-epithelial lymphocytic inflammatory infiltrate; 
-Presence of painful and atrophic-erosive oral lesions, at the same time with reticular 
ones; 
-Previous failure of therapies with topical steroids; 
-Ability to complete the present trial. 
The exclusion criteria were: 
-Presence of histological signs of dysplasia; 
-Use of lichenoid reaction inducing drugs and presence of amalgam fillings close to 
lesions; 
-Therapy for OLP in the 2 months prior to the study; 
- Pregnant or breast feeding women; 
-Proved or suspected hypersensitivity caused by the tested chemicals. 
Preparations 
1st arm. Hydroxyethyl cellulose was melted in boiled water and slowly turned. After few 
hours, the 4% hydroxyethyl cellulose gel was mixed with an equivalent amount of 
pimecrolimus (Elidel® 1% cream, Novartis Farma S.p.A., Orrigo, Varese, Italy) ) to achieve 
a final concentrations containing 0.5% of the drug. 
2nd arm. Hydroxyethyl cellulose was melted in boiled water and slowly turned. After few 
hours, the 4% hydroxyethyl cellulose gel was mixed with an equivalent amount of 
tacrolimus ointment (Protopic® 0.1% ointment, Astellas Pharma S.p.A, Carugate, Milano 
Italy) to achieve a final concentrations containing 0.05% of the drug. 
For both groups, every dose consisted of a quantity of formulation (2 ml), so that 0.5 mg 
per dose of administered medication was obtained.  
Intervention 
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The drugs were applied twice daily for 2 months. All patients were carefully instructed how 
to apply the medications: finger rub application on dried lesions after meals without eating, 
drinking or speaking for at least half an hour afterwards. Anti-mycotic treatment was added 
to the therapy of both groups, consisting of miconazole gel (Daktarin® 2% oral gel, 
Janssen-Cilag S.p.A., Cologno Monzese, Milano, Italy) applied once daily plus 0.12% 
chlorhexidine mouth rinse without alcohol (Curasept A.D.S. 0.12%®, Curaden Healthcare 
S.r.l., Saronno, Varese, Italy) three times daily. Patients were given a written description in 
which the modalities of application were reported and also a paper in which they had to 
mark the two daily administrations. At the end of the protocol, they had to give back the 
marked paper to the examiners. We only accepted cases in which two applications were 
missed, but not consecutive. 
In order to evaluate possible systemic absorption, 8:00 a.m. blood tacrolimus levels were 
monitored at the beginning and at the end of the protocol; we were unable to monitor the 
pimecrolimus levels because in our institution is a not a routinely exam possible to 
prescribed. 
Evaluation 
Clinical evaluation was performed by a single physician (M.C.). Each patient was 
examined by means of record chart compilation, oral examination, registration of 
symptoms and clinical sings, and photo at the beginning of therapy, and then every two 
weeks during the two months of treatment and every 3 months during the follow up period. 
The clinical data were scored according to the criteria scale used by Thongprasom and co-
workers:15 
Score 0: no lesions 
Score 1: hyperkeratotic lesions 
Score 2: atrophic area ≤ 1 cm² 
Score 3: atrophic area > 1 cm² 
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Score 4: erosive area ≤  1 cm² 
Score 5: erosive area > 1 cm² 
Complete resolution of the clinical signs (complete response) was defined as the 
disappearance of all atrophic-erosive lesions, regardless of any persisting hyperkeratotic 
lesions; scores were either zero or one. 
The symptoms score was obtained using a Visual Analogue Scale (VAS). The VAS 
consisted of a 10 cm-horizontal line marked 0 (= no pain) to 10 (= most severe pain ever 
experienced). Patients were requested to mark the scale at each visit. Complete resolution 
of the symptoms (no symptoms) was defined as the absence of any discomfort, 
corresponding to a zero VAS score.  
Partial response, worsening, or persisting of the patient’s condition meant a decrease, an 
increase, or no change at all in the patient’s score.  
The difference between baseline and endpoint scores numerically expresses the clinical 
and symptomatic improvement. 
The stability of the obtained result in the 6 months following the suspension of treatment 
was assessed; the differences between the two groups, when present, were also 
evaluated. 
Cost assessment  
 
We evaluated the total cost of the two treatments: this included the cost of buying the 
drugs and the cost of preparing them with the adhesive medium. All the dressings were 
prepared by the same pharmacy. Each patient used two tubes of a given drug (one per 
month during the trial). The cost of antimycotics was not included in this evaluation as both 
the tacrolimus- and pimecrolimus-treated patients used the same amount of antimycotic 
drugs (data not shown). 
Statistical analysis 
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The sample size was calculated according to previously published16 data suggesting an 
overall efficacy of 80% and 30% for topically applied tacrolimus and pimecrolimus, 
respectively. With a power of 95% and a type I error of 0.05, 30 patients (15 for each arm 
of the study) had to be recruited. Χ2 analysis (with Yates’ correction or Mantel-Haenszel’s 
correction) or Fisher’s exact test were used to compare the responses between the 
groups. P < 0.05 was considered to be statistically significant. 
 
Results 
Thirty consecutive Caucasian patients (23 women, 7 men, mean age 67.75) were enrolled 
in our study; 1 (pimecrolimus group) did not complete the study because of personal 
choice. Fig. 1 shows participant flow. However, this case has been also added in the 
statistical analysis and considered as a treatment failure. 
Demographics and clinical characteristics are detailed in Table 1. There were no 
significant differences between the two groups with regards to age, gender, or clinical and 
symptomatic characteristics at baseline. 
Symptoms improved in all tacrolimus and pimecrolimus treated patients (100%) during the 
first 2 months of therapy, with no statistical differences between the two groups. Complete 
remission of symptoms occurred in 4 patients in both groups (26% and 28% in tacrolimus 
and pimecrolimus group, respectively) (Table 2; Fig. 2). 
Regarding clinical signs, 14 of the 15 tacrolimus treated patients (93%) improved after 2 
months of therapy, while 11 of the 14 pimecrolimus treated patients (78%) had a positive 
response (Fig. 3 and Fig. 4); however, the difference was not statistically significant (P > 
0.05, Fisher’s exact test). In particular, 5 patients treated with Tacrolimus (33%) and 5 
treated with Pimecrolimus (35%) had a complete remission of the athrophic-erosive 
lesions (score 0 or 1) (Table 3; Fig. 5). Both drugs caused a significant reduction of signs 
and symptoms after the first two weeks of treatment with no statistical difference. 
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At the end of the trial, some adverse effects were noted; in the tacrolimus group, 2 patients 
reported mucosal burning sensation during the first days of the therapy and 1 reported a 
transient sialorrhoea. In the pimecrolimus group, 2 patients reported xerostomia, 2 
experienced episodes of gastroesophageal reflux and one the recurrence of two lesions of 
herpes labialis. None of these adverse effects was severe enough to require 
discontinuation of therapy. There was no statistically significant differences between the 
two groups in the incidence of adverse effects (P>0.05, Fisher’s exact test). During 
treatment, blood tacrolimus levels remained undetectable (<1.5ng/mL) or low (<5ng/mL) 
(data not shown). 
Finally, we evaluated a parameter of compliance (e.g. number of missed application) 
without any significant difference between different groups and also in the same arm (data 
not showed). None of the patients had particular difficulty in applying the medications. 
Six months after the end of the therapy, 11 patients treated with tacrolimus (73.33%) 
needed to be retreated due to reactivation of the disease, whereas 10 patients treated with 
pimecrolimus were stable and did not need a new therapy, revealing a significantly better 
stability of the therapeutic efficacy of the latter (Table 4). 
Each patient in both group used an average of 4 ml of drug daily. The cost of a single 
tube of tacrolimus in adhesive medium was 92.79 €, whereas a single tube of 
pimecrolimus costs 93.73 €. The daily cost of tacrolimus treatment was 1.65 € and it was 
comparable to that of pimecrolimus therapy which was 1.67 €. 
 
Discussion 
Usually, patients with OLP are treated with medications that were neither developed nor 
planned for oral diseases, consequently satisfactory efficacy studies are missing. The 
most habitually employed agents for the treatment of OLP are topical corticosteroids. 
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However, independently from the active principle used and the way of administration, 
beyond the half of the responsive patients showed yet again active painful disease, and 
can need new therapeutic approach, confirming the OLP chronic course and the 
symptomatic character of therapeutic treatments. Moreover, some patients are refractory 
to steroid medication and could need a different approach. 
The non-steroidal topical calcineurin inhibitors (TCIs) are important treatment option and 
are indicated in cases where the use of topical steroids is unsuitable, or have failed to 
adequately control OLP, especially in the acute phase, similarly to other dermatological 
conditions.17 Calcineurin inhibitors are microbial derived immunosuppressive medication, 
mainly used in transplant medicine and in the treatment of immune-mediated diseases. To 
date however, there is much debate about their long term efficacy and safety and their 
advantage with respect to conventional therapies.16 Topical pimecrolimus and topical 
tacrolimus have been reported to be successful in treating OLP,18-37 but there are no 
published data comparing their efficacy. We chose two different concentrations of 
pimecrolimus and tacrolimus following the recommendations of previous reported works 
and of pharmaceutical firms. 
In the present study, we can say that both drugs, at these doses, were effective at 
inducing clinical improvement in patients affected by atrophic erosive lesions, with no 
statistical difference.  
The compliance of the tacrolimus arm was slightly better due to the lower incidence of 
adverse effects, even if  this did not reach statistical significant difference and the adverse-
effects were however mild in most cases and did not cause patients to leave the study. 
Topical calcineurin inhibitors occasionally are used within the mouth; the more frequently 
reported adverse event is transient burning sensation (similar to our cases); other minor 
adverse events published can vary and in our series the salivary problems, 
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gastroesophageal reflux and herpes reactivation should have been simply not related 
effects. 
Our data confirmed that the reduction of symptoms in OLP patients following treatment 
with topical pimecrolimus or tacrolimus is generally noticeable; moreover, as previously 
reported, the side-effects are limited and no serious toxicities have been described.38 The 
daily cost of the two medications is similar, less than cyclosporine but still more than five 
times higher than clobetasol (1,82 € and 0,35 € respectively as reported by Conrotto and 
co-workers10). To date, because of the non-existing evidence that TCIs are better than 
topical corticosteroids in reducing pain and clinical sings in patients with erosive OLP, and 
because of their cost, pimecrolimus and tacrolimus should be use as second-line 
treatment for symptomatic OLP, after failure of topical steroids. 
It has been reported that the severity of the oral erosions could impair the barrier function 
of the mucosa and promote the systemic absorption of tacrolimus.39 However, systemic 
absorption of tacrolimus after topical application on the oral mucosa are unpredictable, low 
and with probably very limited clinical significance.17 In our series, low blood level of 
tacrolimus were detected in less than 50% of patients, but this haematological presence 
was not associated with severe adverse events. For technical reasons, we were unable to 
monitor the pimecrolimus blood level; however, recent studies did not showed relevant 
changes in laboratory values of pimecrolimus from baseline,18,24 suggesting that this drug 
could be difficulty absorbed by the oral mucosa. Moreover, it has been reported that the 
permeation of pimecrolimus in corticosteroid pre-treated skin is lower than that of 
tacrolimus. 
As OLP tends to frequently relapse after cessation of treatment, long-lasting property and 
effects of these new medications have to be carefully analysed. During follow up we 
observed that tacrolimus patients were less stable than pimecrolimus patients. 
Pimecrolimus creams revealed a significantly better stability of the therapeutic 
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effectiveness during a period of six months. As already reported, the ability of 
pimecrolimus to permeate the skin to a lesser extent than tacrolimus may contribute to the 
sustained therapeutic effect observed.19, 40 However, literature data about the long-lasting 
benefits of TCIs are nowadays missing. Most of the studies have a short follow-up 
period19,24 and others do not evaluate patients for relapse of disease after discontinuation 
of medications.18 It has been reported that, although topical pimecrolimus and tacrolimus 
are secure and successful for OLP that not respond to topical steroids, existing evidence 
suggests that these agents will not provide long-term resolution.16 Moreover, it has been 
reported that the maintenance of disease remission necessitates continued intermittent 
use of topical tacrolimus, in order to obtain a long lasting action of this medication.34 
However, our data demonstrated that probably this is incorrect at least for pimecrolimus, 
but further studies are needed with more patients and with a long follow-up period. 
As previously used with topical steroids,10,11 we added the hydroxyethylcellulose (HEC) 
with the drugs, in order to make the application more stable and manageable; HEC is 
a naturally derived polymer that is used as a thickener in creams and lotions and helps 
modify viscosity and form gels with water-soluble ingredients.41 Both drugs were mixed 
without any particular technical hitches, even if tacrolimus (provided as homogeneous, 
viscous and semi-solid ointment) was more difficult to incorporate rather than 
pimecrolimus.  Any possible differences due to the incorporation of HEC in the two tested 
medication were considered as irrelevant, based on the lack of any previously reported 
changes in the pharmacological properties of ointment or cream after mixing with HEC. 
However, because of the impossibility to check for the solubility of the two medications in 
the HEC, our results should be interpreted with caution, and, in future, it would be 
interesting to know if the statement achieved would be the same with different preparation 
and different concentrations.  
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Calcineurin inhibitors have been shown to have oncogenic properties mainly linked to the 
production of cytokines that promote tumour growth, metastasis and angiogenesis.18 
Usually, however, the systemic forms are known to increase the risk of malignancy16 and 
currently there is no strong evidence that topical applications could be associated with an 
increased risk of tumours. 
Of course one of the main limitations of our study is the small sample size, which could 
result in limited power, particularly for multivariate analyses. However, it is important to 
remember that our population is exceptionally selected, because of the previous and 
unsuccessful treatment with topical steroids. 
In conclusion, both pimecrolimus and tacrolimus would currently appear to be a treatment 
of choice for patients with atrophic-erosive OLP, previously treated with topical steroids but 
unresponsive; moreover, no unexpected adverse events were reported and the rates of 
adverse events were generally low in both treatment groups. Pimecrolimus seemed to be 
more effective in providing long-term resolution of sings and symptoms. More research is 
however needed to obtain objective evidence of the benefit of TCIs in the treatment of 
immunologically mediated oral mucosal lesion such as erosive OLP, and this work needs 
to be reconfirmed by a large scale clinical trial. 
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